Mankind Pharma Merger & Restructuring Worth ₹500 Cr

Mankind Pharma Earnings Call Transcript: Key Takeaways

Mankind Pharma delivered robust Q2 growth driven by chronic therapies and B-Spec specialty expansion. Strong operating leverage and margin expansion offset muted consumer health performance.

Call

Guides 20% growth

Mankind Pharma Investor Presentation: Key Takeaways

Q2 FY27 revenue ₹4,338 Cr (+17.3% YoY), EBITDA ₹1,175 Cr (27.1% margin), PAT ₹716 Cr (+37.7%). Domestic ex-CH +15.9%, exports +32.7%, CH +1.2%.

Mankind Pharma Results Update

Mankind Pharma reported Q2 FY27 revenue of ₹4,338 Cr, up 17% YoY, and PAT of ₹716 Cr, up 38%. EBITDA margin improved 210 bps to 27.1%.

Mankind Pharma Acquisition

Mankind Pharma's board approved amalgamation of two wholly owned subsidiaries into the parent and a step-down subsidiary merger into MCPPL. Schemes require NCLT and shareholder approvals.

Mankind Pharma Q2 FY27 Results: Net Profit ₹716.1 Cr, Up 37.7% YoY

Mankind Pharma Ltd reported revenue from operations of ₹4,338 Cr (+17.3% YoY) and net profit of ₹716.1 Cr (+37.7% YoY) for Q2 FY27.

Key figure

Net profit ₹716.1 Cr · +37.7% YoY

Mankind Pharma Other Announcement

Mankind Pharma Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.

Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr

Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.

Value

₹2.75 Cr

Execution

Completion expected by 26 January 2027

TVS Holdings Merger & Restructuring

TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.

Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr

Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.

Value

₹30.00 Cr

Execution

Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals

Fortis Healthcare Merger & Restructuring Worth ₹277 Cr

Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.

Value

₹277.0 Cr

Vraj Iron & Steel Merger & Restructuring Worth ₹4.55 Cr

Vraj Iron and Steel transferred 396,000 MVK Industries shares to promoter Gopal Sponge for Rs 4.55 Crore. The sale was completed on October 28, 2026.

Value

₹4.55 Cr

KPIT Technologies Merger & Restructuring Worth ₹19.2 Cr

KPIT Technologies will incorporate a new Vietnam subsidiary for mobility engineering, with 100% control. The company commits USD 2 million (about Rs 19.20 Crore) in cash.

Value

₹19.20 Cr